Literature DB >> 27960086

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.

Jonathon Torchia1, Brian Golbourn2, Shengrui Feng3, King Ching Ho4, Patrick Sin-Chan1, Alexandre Vasiljevic5, Joseph D Norman4, Paul Guilhamon6, Livia Garzia7, Natalia R Agamez4, Mei Lu4, Tiffany S Chan1, Daniel Picard4, Pasqualino de Antonellis7, Dong-Anh Khuong-Quang8, Aline C Planello6, Constanze Zeller6, Dalia Barsyte-Lovejoy6, Lucie Lafay-Cousin9, Louis Letourneau10, Mathieu Bourgey10, Man Yu11, Deena M A Gendoo4, Misko Dzamba12, Mark Barszczyk11, Tiago Medina6, Alexandra N Riemenschneider13, A Sorana Morrissy7, Young-Shin Ra14, Vijay Ramaswamy4, Marc Remke4, Christopher P Dunham15, Stephen Yip16, Ho-Keung Ng17, Jian-Qiang Lu18, Vivek Mehta19, Steffen Albrecht20, Jose Pimentel21, Jennifer A Chan22, Gino R Somers23, Claudia C Faria24, Lucia Roque25, Maryam Fouladi26, Lindsey M Hoffman27, Andrew S Moore28, Yin Wang29, Seung Ah Choi30, Jordan R Hansford31, Daniel Catchpoole32, Diane K Birks27, Nicholas K Foreman27, Doug Strother33, Almos Klekner34, Laszló Bognár34, Miklós Garami35, Péter Hauser35, Tibor Hortobágyi36, Beverly Wilson33, Juliette Hukin37, Anne-Sophie Carret38, Timothy E Van Meter39, Eugene I Hwang40, Amar Gajjar41, Shih-Hwa Chiou42, Hideo Nakamura43, Helen Toledano44, Iris Fried45, Daniel Fults46, Takafumi Wataya47, Chris Fryer37, David D Eisenstat33, Katrin Scheinemann48, Adam J Fleming48, Donna L Johnston49, Jean Michaud50, Shayna Zelcer51, Robert Hammond52, Samina Afzal53, David A Ramsay52, Nongnuch Sirachainan54, Suradej Hongeng54, Noppadol Larbcharoensub55, Richard G Grundy56, Rishi R Lulla57, Jason R Fangusaro57, Harriet Druker58, Ute Bartels58, Ronald Grant58, David Malkin59, C Jane McGlade60, Theodore Nicolaides61, Tarik Tihan62, Joanna Phillips62, Jacek Majewski63, Alexandre Montpetit10, Guillaume Bourque63, Gary D Bader64, Alyssa T Reddy65, G Yancey Gillespie66, Monika Warmuth-Metz67, Stefan Rutkowski68, Uri Tabori69, Mathieu Lupien3, Michael Brudno70, Ulrich Schüller71, Torsten Pietsch72, Alexander R Judkins73, Cynthia E Hawkins74, Eric Bouffet4, Seung-Ki Kim30, Peter B Dirks13, Michael D Taylor75, Anat Erdreich-Epstein76, Cheryl H Arrowsmith6, Daniel D De Carvalho77, James T Rutka78, Nada Jabado79, Annie Huang80.   

Abstract

We recently reported that atypical teratoid rhabdoid tumors (ATRTs) comprise at least two transcriptional subtypes with different clinical outcomes; however, the mechanisms underlying therapeutic heterogeneity remained unclear. In this study, we analyzed 191 primary ATRTs and 10 ATRT cell lines to define the genomic and epigenomic landscape of ATRTs and identify subgroup-specific therapeutic targets. We found ATRTs segregated into three epigenetic subgroups with distinct genomic profiles, SMARCB1 genotypes, and chromatin landscape that correlated with differential cellular responses to a panel of signaling and epigenetic inhibitors. Significantly, we discovered that differential methylation of a PDGFRB-associated enhancer confers specific sensitivity of group 2 ATRT cells to dasatinib and nilotinib, and suggest that these are promising therapies for this highly lethal ATRT subtype.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATRT; enhancer; epigenomics; genomics; rhabdoid tumors; subgroup-specific therapeutics

Mesh:

Substances:

Year:  2016        PMID: 27960086      PMCID: PMC5500911          DOI: 10.1016/j.ccell.2016.11.003

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  42 in total

1.  A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish.

Authors:  Andrea Geling; Harald Steiner; Michael Willem; Laure Bally-Cuif; Christian Haass
Journal:  EMBO Rep       Date:  2002-07       Impact factor: 8.807

2.  Radial glia serve as neuronal progenitors in all regions of the central nervous system.

Authors:  Todd E Anthony; Corinna Klein; Gord Fishell; Nathaniel Heintz
Journal:  Neuron       Date:  2004-03-25       Impact factor: 17.173

Review 3.  The SWI/SNF complex--chromatin and cancer.

Authors:  Charles W M Roberts; Stuart H Orkin
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

Review 4.  The epigenetic progenitor origin of human cancer.

Authors:  Andrew P Feinberg; Rolf Ohlsson; Steven Henikoff
Journal:  Nat Rev Genet       Date:  2006-01       Impact factor: 53.242

5.  Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy.

Authors:  Tanya M Tekautz; Christine E Fuller; Susan Blaney; Maryam Fouladi; Alberto Broniscer; Thomas E Merchant; Matthew Krasin; James Dalton; Gregory Hale; Larry E Kun; Dana Wallace; Richard J Gilbertson; Amar Gajjar
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

6.  The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression.

Authors:  A Klochendler-Yeivin; L Fiette; J Barra; C Muchardt; C Babinet; M Yaniv
Journal:  EMBO Rep       Date:  2000-12       Impact factor: 8.807

7.  Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5.

Authors:  Charles W M Roberts; Monique M Leroux; Mark D Fleming; Stuart H Orkin
Journal:  Cancer Cell       Date:  2002-11       Impact factor: 31.743

8.  Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry.

Authors:  Joanne M Hilden; Sharon Meerbaum; Peter Burger; Jonathan Finlay; Anna Janss; Bernd W Scheithauer; Andrew W Walter; Lucy B Rorke; Jaclyn A Biegel
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

9.  Abnormal function of astroglia lacking Abr and Bcr RacGAPs.

Authors:  V Kaartinen; I Gonzalez-Gomez; J W Voncken; L Haataja; E Faure; A Nagy; J Groffen; N Heisterkamp
Journal:  Development       Date:  2001-11       Impact factor: 6.868

10.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

Authors:  Hagop Kantarjian; Francis Giles; Lydia Wunderle; Kapil Bhalla; Susan O'Brien; Barbara Wassmann; Chiaki Tanaka; Paul Manley; Patricia Rae; William Mietlowski; Kathy Bochinski; Andreas Hochhaus; James D Griffin; Dieter Hoelzer; Maher Albitar; Margaret Dugan; Jorge Cortes; Leila Alland; Oliver G Ottmann
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

View more
  75 in total

1.  Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy.

Authors:  Harinad B Maganti; Hani Jrade; Christopher Cafariello; Janet L Manias Rothberg; Christopher J Porter; Julien Yockell-Lelièvre; Hannah L Battaion; Safwat T Khan; Joel P Howard; Yuefeng Li; Adrian T Grzybowski; Elham Sabri; Alexander J Ruthenburg; F Jeffrey Dilworth; Theodore J Perkins; Mitchell Sabloff; Caryn Y Ito; William L Stanford
Journal:  Cancer Discov       Date:  2018-08-16       Impact factor: 39.397

2.  Pediatric Atypical Teratoid/Rhabdoid Tumors of the Brain: Identification of Metabolic Subgroups Using In Vivo 1H-MR Spectroscopy.

Authors:  B Tamrazi; S Venneti; A Margol; D Hawes; S Y Cen; M Nelson; A Judkins; J Biegel; S Blüml
Journal:  AJNR Am J Neuroradiol       Date:  2019-04-04       Impact factor: 3.825

Review 3.  Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.

Authors:  Francesco Ceppi; Maja Beck-Popovic; Jean-Pierre Bourquin; Raffaele Renella
Journal:  Eur J Pediatr       Date:  2017-08-12       Impact factor: 3.183

4.  SWI/SNF complex differences promote cellular heterogeneity in rhabdoid tumors.

Authors:  Charles G Eberhart; Jeffrey A Rubens
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

5.  Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children's Oncology Group Trial ACNS0333.

Authors:  Alyssa T Reddy; Douglas R Strother; Alexander R Judkins; Peter C Burger; Ian F Pollack; Mark D Krailo; Allen B Buxton; Chris Williams-Hughes; Maryam Fouladi; Anita Mahajan; Thomas E Merchant; Ben Ho; Claire M Mazewski; Victor A Lewis; Amar Gajjar; Louis-Gilbert Vezina; Timothy N Booth; Kerry W Parsons; Vicky L Poss; Tianni Zhou; Jaclyn A Biegel; Annie Huang
Journal:  J Clin Oncol       Date:  2020-02-27       Impact factor: 44.544

6.  Targeting MEK/MELK in atypical teratoid rhabdoid tumor: a treatment approach aimed at exploiting blood-brain barrier deficiencies.

Authors:  Dean Popovski; Annie Huang
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

7.  Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.

Authors:  Isabel Tegeder; Katharina Thiel; Serap Erkek; Pascal D Johann; Johannes Berlandi; Venu Thatikonda; Michael C Frühwald; Marcel Kool; Astrid Jeibmann; Martin Hasselblatt
Journal:  J Neurooncol       Date:  2018-11-16       Impact factor: 4.130

8.  SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors.

Authors:  Pooja Panwalkar; Drew Pratt; Chan Chung; Derek Dang; Paul Le; Daniel Martinez; Jill M Bayliss; Kyle S Smith; Mike Adam; Steven Potter; Paul A Northcott; Leo Mascarenhas; Jared Shows; Bruce Pawel; Ashley Margol; Annie Huang; Alexander R Judkins; Sriram Venneti
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

9.  Subgroup-specific outcomes of children with malignant childhood brain tumors treated with an irradiation-sparing protocol.

Authors:  Eveline Teresa Hidalgo; Matija Snuderl; Cordelia Orillac; Svetlana Kvint; Jonathan Serrano; Peter Wu; Matthias A Karajannis; Sharon L Gardner
Journal:  Childs Nerv Syst       Date:  2019-08-02       Impact factor: 1.475

Review 10.  Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors.

Authors:  Sydney T Grob; Jean M Mulcahy Levy
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.